image: The team from the Cognition Biology Research Group at UPF that developed the study.
Credit: Frederic Camallonga - UPF
Ongoing treatment with a drug that inhibits the endocannabinoid system peripherally improves memory deficits, reduces synaptic alterations, mitigates gut microbiota dysbiosis, and restores intestinal barrier integrity markers in fragile X syndrome mouse models. This experimental approach opens the door to studying a potential therapy to improve the cognitive ability of people that have the syndrome and underscores the role that alterations to the microbiota–gut–brain axis may play in intellectual disability.
Fragile X syndrome is the most common monogenic cause of inherited intellectual disability and autism spectrum disorder. In Spain, it affects around 10,000 people who, to varying degrees, present with memory impairment, hyperactivity, impulsiveness, gastrointestinal dysfunction or autistic-type behaviour, among others. To date, there is no treatment for cognitive impairment caused by this syndrome, of which an estimated 127,000 people in Spain are carriers.
Now, a study by the Cognition Biology Research Group at Pompeu Fabra University, published in the journal Translational Psychiatry, reveals that a one-week experimental treatment in mice improves the neuronal connections and cognitive abilities of animals affected by the syndrome, and restores the microbiota and intestinal barrier of the treated animals.
“Unlike other drugs that act on the brain, the compound we have tested acts only on peripheral type 1 cannabinoid (CB1) receptors”, outlines Andrés Ozaita, director of the Cognition Biology Research Group and principal investigator. In the same way as in treatments that act on the brain, in mice with the fragile X mutation, this peripheral treatment enhances memory and increases plasticity, which improves the quality of neuronal connections in the hippocampus.
“Seeing that the results are comparable to those obtained using drugs that act on the whole body, we think that the main effect of broad-spectrum drugs is closely linked to their peripheral action”, the UPF professor points out.
Effects on the microbiota and the intestinal lining
As occurs with other neurodevelopmental disorders, fragile X syndrome is associated with certain gastrointestinal disorders.
The study found that the faeces of fragile X mutation mice, and therefore their intestines, contain fewer bacteria of the genera Lactobacillus and Akkermansia, as well as a reduced expression of the Muc2 gene, an essential protein for the intestinal mucosa to maintain its function as a physical barrier as well as communication with the immune system.
Although most of the body’s CB1 receptors are located in the brain –which contains 10 times more receptors than the other organs– they are distributed throughout the body, and their peripheral (non-cerebral) inhibition also improves the gut ecosystem.
“Peripheral pharmacological treatment helps restore the microbiome of mutated mice and increases the expression of the Muc2 gene. These two actions improve the ecosystem and the barrier of the large intestine”, explains Lucía de los Reyes Ramírez, co-first author of the study.
“We cannot state that this recovery of the intestinal environment is due to the specific inhibition of the CB1 receptors in the intestine, but we can say that peripheral inhibition has a positive effect on the microbiota-gut-brain axis in mice carrying the fragile X mutation”, explains Araceli Bergadà-Martínez, also co-first author of the study.
Towards a potential therapy
The study proposes an experimental treatment. However, the results in terms of improved cognitive function, the gut microenvironment and the potential absence of adverse central effects make continuing to study this pharmacological approach worthwhile.
In addition, the results of the study invite the exploration of whether the compounds that inhibit cannabinoid receptors and act throughout the body mainly affect the gut. Clarifying all the above questions will be key when it comes to designing a potential therapy for humans.
Journal
Translational Psychiatry
Method of Research
Experimental study
Subject of Research
Animals
Article Title
A serotonergic mechanism is involved in the pro-cognitive effect of AM6545 treatment in a mouse model of fragile X syndrome
Article Publication Date
20-Aug-2026
COI Statement
RM and AO declare intellectual property of the patent PCT/EP2013/055728. The remaining authors declare no conflict of interest.